C12N 2710/24122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 222 US grants and 260 published applications in this corpus.
Search patents in C12N- Granted patents
- 222
- Published applications
- 260
- Assignees
- 154
- Inventors
- 430
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 16 | 0 |
| 1999 | 11 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 3 | 5 |
| 2003 | 6 | 15 |
| 2004 | 5 | 4 |
| 2005 | 4 | 9 |
| 2006 | 9 | 14 |
| 2007 | 6 | 14 |
| 2008 | 8 | 7 |
| 2009 | 8 | 23 |
| 2010 | 9 | 14 |
| 2011 | 16 | 16 |
| 2012 | 11 | 13 |
| 2013 | 13 | 18 |
| 2014 | 8 | 8 |
| 2015 | 11 | 8 |
| 2016 | 7 | 5 |
| 2017 | 4 | 9 |
| 2018 | 7 | 8 |
| 2019 | 4 | 5 |
| 2020 | 10 | 12 |
| 2021 | 7 | 9 |
| 2022 | 4 | 8 |
| 2023 | 4 | 10 |
| 2024 | 5 | 10 |
| 2025 | 1 | 5 |
| 2026 | 4 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeted antigen delivery system and uses thereof26 May 2026US 12,636,378 B2SRI International
- Tumor-targeting A56 protein or fragment thereof, antibody binding to A56 protein, and use thereof28 Apr 2026US 12,612,448 B2Bionoxx Inc.
- Synthetic chimeric vaccinia virus20 Jan 2026US 12,529,036 B2Tonix Pharma Limited
- Immuno-oncolytic therapies6 Jan 2026US 12,514,888 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors26 Aug 2025US 12,397,029 B2Memorial Sloan Kettering Cancer Center
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Multi-antigen chimeric vaccine against poxvirus and use thereof20 Aug 2026US 2026/0240989 A1Institute of Microbiology, Chinese Academy of Sciences
- Recombinant chimeric antigen for poxvirus, subunit vaccine comprising same and use thereof6 Aug 2026US 2026/0226110 A1Beihang University
- Modified immunization vectors30 Jul 2026US 2026/0218234 A1
- Mrna recombinant capping enzymes16 Jul 2026US 2026/0201350 A1Sanofi Pasteur Limited
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Recombinant MVA vaccinia virus120US 5,185,146 AHoffmann-LaRoche Inc. · 1993
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001